- Home
- VCIG vs TENX Comparison
VCIG vs TENX Comparison
Compare VCIG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- TENX
- Stock Information
- Founded
- VCIG 2013
- TENX 1967
- Country
- VCIG Malaysia
- TENX United States
- Employees
- VCIG 58
- TENX N/A
- Industry
- VCIG Diversified Commercial Services
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- TENX Health Care
- Exchange
- VCIG Nasdaq
- TENX Nasdaq
- Market Cap
- VCIG 21.7M
- TENX 25.8M
- IPO Year
- VCIG 2023
- TENX N/A
- Fundamental
- Price
- VCIG $0.81
- TENX $5.97
- Analyst Decision
- VCIG
- TENX Strong Buy
- Analyst Count
- VCIG 0
- TENX 3
- Target Price
- VCIG N/A
- TENX $15.00
- AVG Volume (30 Days)
- VCIG 3.8M
- TENX 25.8K
- Earning Date
- VCIG 08-26-2025
- TENX 08-13-2025
- Dividend Yield
- VCIG N/A
- TENX N/A
- EPS Growth
- VCIG N/A
- TENX N/A
- EPS
- VCIG 54.73
- TENX N/A
- Revenue
- VCIG $27,819,290.00
- TENX N/A
- Revenue This Year
- VCIG N/A
- TENX N/A
- Revenue Next Year
- VCIG N/A
- TENX N/A
- P/E Ratio
- VCIG $0.01
- TENX N/A
- Revenue Growth
- VCIG 36.99
- TENX N/A
- 52 Week Low
- VCIG $0.75
- TENX $3.25
- 52 Week High
- VCIG $264.60
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- VCIG 32.75
- TENX 48.76
- Support Level
- VCIG $0.75
- TENX $5.82
- Resistance Level
- VCIG $0.93
- TENX $5.95
- Average True Range (ATR)
- VCIG 0.10
- TENX 0.21
- MACD
- VCIG 0.05
- TENX -0.03
- Stochastic Oscillator
- VCIG 11.08
- TENX 37.62
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.